BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Clavé MM, Maeda NY, Thomaz AM, Bydlowski SP, Lopes AA. Phosphodiesterase type 5 inhibitors improve microvascular dysfunction markers in pulmonary arterial hypertension associated with congenital heart disease. Congenit Heart Dis 2019;14:246-55. [PMID: 30343508 DOI: 10.1111/chd.12688] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Xi SB, Wang SS, Qian MY, Xie YM, Li JJ, Zhang ZW. Predictors of operability in children with severe pulmonary hypertension associated with congenital heart disease. Chin Med J (Engl) 2019;132:811-8. [PMID: 30789367 DOI: 10.1097/CM9.0000000000000145] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
2 Constantine A, Condliffe R, Clift P, Tulloh R, Dimopoulos K; CHAMPION Steering Committee. Palliative care in pulmonary hypertension associated with congenital heart disease: systematic review and expert opinion. ESC Heart Fail 2021;8:1901-14. [PMID: 33660435 DOI: 10.1002/ehf2.13263] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Davizon-Castillo P, Allawzi A, Sorrells M, Fisher S, Baltrunaite K, Neeves K, Nozik-Grayck E, DiPaola J, Delaney C. Platelet activation in experimental murine neonatal pulmonary hypertension. Physiol Rep 2020;8:e14386. [PMID: 32163236 DOI: 10.14814/phy2.14386] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Chen N, Zhou L, Huang J, Yu W, Chen C, Jin H, Shi X, Yu Z, Liu Q, Yang Y, Wang Z, Shi J. Identifying multimorbidity patterns of non-communicable diseases in paediatric inpatients: a cross-sectional study in Shanghai, China. BMJ Open 2021;11:e042679. [PMID: 33795295 DOI: 10.1136/bmjopen-2020-042679] [Reference Citation Analysis]